OPKO Health, Inc. (OPK)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 2
Do Nothing: fundamentalScore is 2 (below required floor of 3), and ADX14 failed to load, so the technical read is degraded and no bullish entry can be scored.
Company overview
OPKO Health, Inc. is a healthcare company focused on diagnostics and pharmaceuticals, operating in the U.S. and international markets. Its Diagnostics division includes BioReference Laboratories, providing laboratory testing services. The Pharmaceutical segment offers products like Rayaldee and has a development pipeline including treatments for diabetes and growth hormone deficiencies.
Fundamental
weakOPKO Health faces multi-year revenue decline and ongoing losses, with high regulatory and commercialization risks.
FundamentalScore 2/5: SEC filings show a multi-year revenue contraction (FY2025 revenue ~$606.9M) and continued annual losses, partially offset by solid liquidity (cash ~$314M at 2026-06-30 and current ratio ~3.35). High biotech/regulatory and commercialization risk remains; valuation and intrinsic-value signals are limited in this run due to missing standardized market/DCF data.
Sentiment
fairMedia sentiment is mixed post-Q2 results, with limited retail engagement and no significant catalysts.
Near-term narrative is still dominated by the Q2 2026 results release (2026-07-27, announced), which the company’s own PR framed cautiously and which remains a mildly bearish overhang as the market digests the numbers. Media tone over the last ~14d is mixed and appears less constructive than the 30–90d baseline (aggregator-heavy and more partnership/pipeline-leaning), while retail chatter is negligible and no severe legal/regulatory red flags surfaced (with some scan coverage gaps).
Technical
weakThe stock is consolidating post-spike with no clear breakout signals, trading below key moving averages.
OPK's chart is mixed after the late-July spike: price is above SMA20 (1.29) and SMA200 (1.29) but below SMA50 (1.38), EMA9 (1.32), EMA21 (1.33) and the latest daily VWAP (~1.33). RSI14 is neutral at 48.8, Williams %R is weak at -75, and MACD is still below zero at -0.01 even though it sits above its -0.02 signal. ADX14 failed to load, so a mandatory trend-strength input is missing and the technical read is capped at 2.
You’re looking at 2026-08-04 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.